# Shanghai ForeFront Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-forefront-pharma

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.forefrontpharma.com/
- Total disclosed funding: $14M
- Latest round: Series B (Dec 29, 2025)
- Investors on record: 3

## About

Shanghai ForeFront Pharmaceutical Co., Ltd. is a pharmaceutical company in China focused on developing and manufacturing a wide range of medications and health solutions for various health conditions.Founded in 2014, Shanghai ForeFront Pharma specializes in pharmaceutical development, particularly in prescription and over-the-counter products. The company is headquartered in Shanghai, China. In December 2025, it secured CNY 100 million in Series B funding from investors including China Grand Pharmaceutical and Healthcare Holdings Limited and Zhongxiaodan Venture Capital. This funding will aid in the commercialization of their core treprostone products.Shanghai ForeFront Pharmaceutical Co., Ltd. specializes in the development and manufacturing of a diverse portfolio of pharmaceutical products aimed at addressing various health conditions. Their core offerings include prescription medications and over-the-counter health solutions that target areas such as infectious diseases, chronic ailments, and pain management. The company focuses on utilizing advanced manufacturing techniques and research to ensure the efficacy and safety of its products. Key end-users include hospitals, healthcare providers, and retail pharmacies, with a growing international client base in Southeast Asia, Europe, and North America.Shanghai ForeFront Pharmaceutical Co., Ltd. generates revenue primarily through direct sales and partnerships with healthcare distributors. The firm engages in B2B transactions with healthcare institutions, which may include bulk purchasing agreements or subscription models for ongoing supply. Key flagship products drive substantial revenue streams, while the company tailors pricing strategies to remain competitive in the pharmaceutical market.In December 2025, Shanghai ForeFront Pharma plans to utilize the recently raised CNY 100 million from its Series B funding to accelerate the launch and commercialization of its core treprostone series of products and other rare disease treatments in China and internationally. The company aims to enhance clinical research and consistency evaluation of its innovative pipelines, as well as optimize its R&D facilities and personnel to support these initiatives.

## Funding rounds

- Series B, Dec 29, 2025, $14M — China Grand Pharmaceutical and Healthcare Holdings Limited, Ningbo Chisage Venture Capital Management Partnership, Zhongxiaodan Venture Capital

## Investors

- China Grand Pharmaceutical and Healthcare Holdings Limited — Series B
- Ningbo Chisage Venture Capital Management Partnership — Series B
- Zhongxiaodan Venture Capital (https://capitalatlas.ai/funds/zhongxiaodan-venture-capital) — Series B